Skip to main content
Fig. 2 | BMC Biology

Fig. 2

From: DDX39B interacts with the pattern recognition receptor pathway to inhibit NF-κB and sensitize to alkylating chemotherapy

Fig. 2

DDX39B regulates NF-κB via MAVS and TRIF. a Luciferase assay using the -1C reporter in primary mouse embryonic fibroblasts (MEFs) isolated from wild-type, MAVS−/−, and Tmem173−/− mice following infection with sh-Ddx39b (Ddx) or non-targeting control. Data show mean relative value, ± SEM of two independent experiments. Inset: IB with anti-DDX39B antibody. b Luciferase assay performed as in a using wild-type, Myd88−/−, and Trif−/− MEFs. Data show mean relative value, ± SEM of two independent experiments. c IB in the indicated MEFs infected with sh-Ddx39b or non-targeting control using anti-phospho-p65 antibody. d Luciferase assay in U87 control or DDX39B CRISPR cells. Data show mean relative value, ± SEM of two independent experiments. e IB in U87 control and DDX39B CRISPR clones transfected with si-MAVS or si-control probed with the indicated antibodies. *P < 0.05, **P < 0.01 (two-tailed t test)

Back to article page